Gilead Sciences
Trade Gilead Sciences 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About GILD
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases.
GILD Key Statistics
Stock Snapshot
The current Gilead Sciences(GILD) stock price is $151.20, with a market capitalization of 187.44B. The stock trades at a price-to-earnings (P/E) ratio of -56.91 and offers a dividend yield of 2.15%.
During the trading session on 2026-10-11, Gilead Sciences(GILD) shares reached a daily high of $151.44 and a low of $146.10. At a current price of $151.20, the stock is +3.5% higher than the low and still -0.2% under the high.
Trading activity shows a volume of 5.8M, compared to an average daily volume of 5.05M.
Over the past 52 weeks, Gilead Sciences(GILD) stock has traded between a high of $157.29 and a low of $114.02.
Over the past 52 weeks, Gilead Sciences(GILD) stock has traded between a high of $157.29 and a low of $114.02.
GILD News
Gilead Sciences (GILD) moved back into focus after a strong quarterly report, with revenue growth topping analyst expectations and management lifting its HIV sa...
Gilead Sciences (GILD Quick QuoteGILD - Free Report) closed at $151.17 in the latest trading session, marking a +2.77% move from the prior day. The stock...
Gilead Sciences reported a strong Q2, with revenue up 10.2% year on year and full year EPS guidance above analyst estimates, and extended a five year DevOps and...
Analyst ratings
77%
of 30 ratingsMore GILD News
Gilead Sciences (NasdaqGS:GILD) extended its AI and DevOps partnership with Cognizant through a new five-year agreement. The Cognizant deal targets broader AI...
Cognizant (CTSH) announced a five-year extension of its work with Gilead Sciences (GILD). Under the agreement, Cognizant will support Gilead’s continued develop...
Nurix Therapeutics (NRIX) announced that Nurix and Gilead (GILD) have agreed to extend the research term for an undisclosed oncology program within the companie...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.